European Commission says recast consultation confirms need for legislative improvements
This article was originally published in SRA
Executive Summary
The European Commission believes that its consultation on a possible recast of the medical device directives has confirmed the need for legislative changes in the medtech regulatory framework, but it agrees with industry stakeholders that more time is needed to draft formal proposals1-3. Formal proposals are unlikely to emerge this year.
You may also be interested in...
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.